Related Experiment Video

Updated: Aug 12, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection?

Gozewijn D Laverman1, Giuseppe Remuzzi, Piero Ruggenenti

  • 1Department of Medicine, Division of Nephrology, University of Groningen, The Netherlands.

Journal of the American Society of Nephrology : JASN
|December 20, 2003
PubMed

Insights

Angiotensin-converting enzyme inhibition and angiotensin receptor blockade offer renoprotection for chronic kidney disease. Combined therapy may enhance long-term benefits, with dose titration being crucial for optimal outcomes.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Chronic renal disease leads to progressive kidney function loss and heightened cardiovascular risk.
  • Renin-angiotensin system (RAS) blockade via ACE inhibitors or ARBs offers renoprotective and cardiovascular benefits, though direct comparison remains debated.
  • Understanding the comparative efficacy of these drug classes is vital for managing kidney disease and associated cardiovascular complications.

Purpose of the Study:

  • To review and compare the renoprotective and cardiovascular effects of ACE inhibitors and ARBs.
  • To evaluate outcomes in non-diabetic renal disease and diabetic nephropathy (type 1 and type 2).
  • To assess the role of combination therapy and drug titration in maximizing patient protection.

Main Methods:

  • Systematic review of studies comparing ACE inhibitors and ARBs.
  • Analysis of both renal and cardiovascular outcomes.
  • Consideration of dose-response relationships and combination therapy effects.

Main Results:

  • Both ACE inhibitors and ARBs demonstrate dose-dependent effects on intermediate renal and cardiovascular parameters.
  • Combined ACE inhibition and ARB therapy appears superior to monotherapy for long-term renoprotection.
  • Maximal protection often necessitates a multidrug regimen, emphasizing full dose titration of RAS blockers.

Conclusions:

  • Optimal renoprotection and cardiovascular protection in chronic kidney disease often requires a comprehensive antihypertensive strategy.
  • Full dose titration of RAS blockers, potentially with add-on therapy, is key, irrespective of the initial drug choice.
  • Combination therapy with ACE inhibitors and ARBs shows promise for enhanced renoprotection compared to monotherapy.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...